HRP20200037T4 - TABLETA KOJA SADRŽI 7-[4- (4-BENZO [b] TIOFEN-4-YL-PIPERAZIN-1-YL) BUTOKSI]-1H-KINOLIN-2-ON ILI NJEGOVU SOL - Google Patents

TABLETA KOJA SADRŽI 7-[4- (4-BENZO [b] TIOFEN-4-YL-PIPERAZIN-1-YL) BUTOKSI]-1H-KINOLIN-2-ON ILI NJEGOVU SOL Download PDF

Info

Publication number
HRP20200037T4
HRP20200037T4 HRP20200037TT HRP20200037T HRP20200037T4 HR P20200037 T4 HRP20200037 T4 HR P20200037T4 HR P20200037T T HRP20200037T T HR P20200037TT HR P20200037 T HRP20200037 T HR P20200037T HR P20200037 T4 HRP20200037 T4 HR P20200037T4
Authority
HR
Croatia
Prior art keywords
weight
tablet
disintegrant
lubricant
binder
Prior art date
Application number
HRP20200037TT
Other languages
English (en)
Inventor
Yoshiharu Inoue
Original Assignee
Otsuka Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48081918&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20200037(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharmaceutical Co., Ltd. filed Critical Otsuka Pharmaceutical Co., Ltd.
Publication of HRP20200037T1 publication Critical patent/HRP20200037T1/hr
Publication of HRP20200037T4 publication Critical patent/HRP20200037T4/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Supply Of Fluid Materials To The Packaging Location (AREA)
  • Basic Packing Technique (AREA)

Claims (7)

1. Tableta koja sadrži 7- [4- (4-benzo [b] tiofen-4-il-piperazin-1-il) butoksi] -1H-kinolin-2-on ili njegovu sol kao aktivni sastojak, pomoćnu tvar (a), vezivo (b), sredstvo za razgradnju (c) i mazivo (d), naznačena time što je pomoćna tvar (a) barem jedan član izabran iz skupine koja se sastoji od laktoze, kukuruznog škroba i mikrokristalne celuloze; vezivo (b) je hidroksipropil celuloza; sredstvo za razgradnju (c) je barem jedan član izabran iz skupine koja se sastoji od nisko supstituirane hidroksipropil celuloze, kroskarmeloza natrija i natrijevog karboksimetil škroba; i mazivo (d) je magnezijev stearat: tableta koja dodatno sadrži premazni sloj na svojoj površini, pri čemu navedeni premazni sloj sadrži bojilo (e), a bojilo (e) sadrži željezov oksid.
2. Tableta u skladu sa zahtjevom 1, koja sadrži: 0.05 do 25% težine 7- [4- (4-benzo [b] tiofen-4-il-piperazin-l-il) butoksi] -lH-kinolin-2-ona ili njegove soli; 10 do 98.5% težine pomoćne tvari (a); 0.1 do 20% težine veziva (b); 1 do 25% težine sredstva za razgradnju (c); i 0.1 do 10% težine maziva (d), u odnosu na težinu obložene tablete prije nanošenja premaza.
3. Tableta u skladu sa zahtjevom 1 ili 2, naznačena time što na 1 težinski dio 7- [4- (4-benzo [b] tiofen-4-il-piperazin-1-il) butoksi] -1H-kinolin-2-on ili njegove soli, tableta sadrži: 1 do 2000 težinskih dijelova pomoćne tvari (a); 0.01 do 100 težinskih dijelova veziva (b); 0.1 do 500 težinskih dijelova sredstva za razgradnju (c); i 0.01 do 50 težinskih dijelova maziva (d).
4. Tableta u skladu sa zahtjevom 4, naznačena time što tableta sadrži 0.1 do 50% težine boje (e) u odnosu na težinu zaštitnog sloja.
5. Tableta u skladu s bilo kojim od zahtjeva 1 do 5, dobivena formiranjem, u tabletu, granulirane tvari dobivene mokrom granulacijom.
6. Tableta prema bilo kojem od zahtjeva 1 do 5, naznačena time što tableta ne sadrži povidon ili krospovidon.
7. Postupak za proizvodnju tableta, postupak uključuje korake: (1) granulacija smjese koja sadrži 7- [4- (4-benzo [b] tiofen-4-il-piperazin-l-il) butoksi] -lH-kinolin-2-on ili njegovu sol, pomoćnu tvar (a), vezivo (b) i sredstvo za razgradnju (c), te daljnjim postupkom umiješano mazivo (d); (2) oblikovanje dobivene smjese u tabletu, i (3) miješanje sredstva za premazivanje, bojila (e) i tekućeg medija za dobivanje smjese za premazivanje, te premazivanje površine tablete smjesom za premazivanje, naznačen time što je pomoćni sastojak (a) barem jedan član izabran iz skupine koja se sastoji od laktoze, kukuruznog škroba i mikrokristalne celuloze; vezivo (b) je hidroksipropil celuloza; sredstvo za razgradnju (c) je barem jedan član izabran iz skupine koja se sastoji od nisko supstituirane hidroksipropil celuloze, kroskarmeloza natrija i natrijevog karboksimetil škroba; i mazivo (d) je magnezijev stearat; i gdje mješavina za premaz sadrži željezov oksid kao bojilo (e).
HRP20200037TT 2011-10-14 2012-10-12 TABLETA KOJA SADRŽI 7-[4- (4-BENZO [b] TIOFEN-4-YL-PIPERAZIN-1-YL) BUTOKSI]-1H-KINOLIN-2-ON ILI NJEGOVU SOL HRP20200037T4 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011227057 2011-10-14
EP12840025.6A EP2767285B2 (en) 2011-10-14 2012-10-12 TABLET COMPRISING 7-[4-(4-BENZO[b]THIOPHEN-4-YL-PIPERAZIN-1-YL) BUTOXY]-1H-QUINOLIN-2-ONE OR A SALT THEREOF
PCT/JP2012/076415 WO2013054872A1 (ja) 2011-10-14 2012-10-12 ７－［４－（４－ベンゾ［ｂ］チオフェン－４－イル－ピペラジン－１－イル）ブトキシ］－１Ｈ－キノリン－２－オン又はその塩を含む錠剤

Publications (2)

Publication Number Publication Date
HRP20200037T1 HRP20200037T1 (hr) 2020-03-20
HRP20200037T4 true HRP20200037T4 (hr) 2025-05-23

Family

ID=48081918

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20200037TT HRP20200037T4 (hr) 2011-10-14 2012-10-12 TABLETA KOJA SADRŽI 7-[4- (4-BENZO [b] TIOFEN-4-YL-PIPERAZIN-1-YL) BUTOKSI]-1H-KINOLIN-2-ON ILI NJEGOVU SOL

Country Status (34)

Country Link
US (8) US20140234417A1 (hr)
EP (1) EP2767285B2 (hr)
JP (2) JP6084161B2 (hr)
KR (1) KR102072371B1 (hr)
CN (2) CN103889425B (hr)
AP (1) AP2014007564A0 (hr)
AR (1) AR088319A1 (hr)
AU (1) AU2012321723C1 (hr)
BR (1) BR112014008603A2 (hr)
CA (1) CA2851588C (hr)
CL (1) CL2014000909A1 (hr)
CO (1) CO6950480A2 (hr)
CY (1) CY1122460T1 (hr)
DK (1) DK2767285T4 (hr)
EA (1) EA032930B1 (hr)
ES (1) ES2762479T5 (hr)
FI (1) FI2767285T4 (hr)
HR (1) HRP20200037T4 (hr)
HU (1) HUE047493T2 (hr)
IL (1) IL231513B (hr)
IN (1) IN2014DN02055A (hr)
JO (1) JO3753B1 (hr)
LT (1) LT2767285T (hr)
MX (1) MX376092B (hr)
MY (1) MY173370A (hr)
PH (1) PH12014500607A1 (hr)
PL (1) PL2767285T5 (hr)
PT (1) PT2767285T (hr)
SG (2) SG2014013783A (hr)
SI (1) SI2767285T2 (hr)
TW (1) TWI634908B (hr)
UA (1) UA114411C2 (hr)
WO (1) WO2013054872A1 (hr)
ZA (1) ZA201402333B (hr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
JP5936732B1 (ja) * 2015-03-05 2016-06-22 日本カラコン合同会社 フィルムコーティング組成物
CN105106142B (zh) * 2015-09-22 2018-05-22 成都欣捷高新技术开发有限公司 一种含有依匹哌唑的冻干口服制剂及其制备方法
CN106994119A (zh) * 2016-01-22 2017-08-01 浙江华海药业股份有限公司 含有依匹哌唑或其盐的口腔崩解片及其制备方法
CA3014090A1 (en) * 2016-02-19 2017-08-24 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof
KR20190022709A (ko) * 2016-06-28 2019-03-06 가부시키가이샤 니폰 고킨 소고 겐큐쇼 부형제 및 정제
CN109475557B (zh) * 2016-07-27 2022-01-07 日本脏器制药株式会社 含有甲氨蝶呤的薄膜包衣片
US11123300B2 (en) * 2016-08-16 2021-09-21 Hexal Ag Immediate release tablet of a benzothiophene compound
US20200093821A1 (en) 2016-08-16 2020-03-26 Hexal Ag Pharmaceutical Compositions of a Benzothiophene Compound
CN106496206A (zh) * 2016-08-31 2017-03-15 安徽省润生医药股份有限公司 一种依匹哌唑新的制备方法
JP7053645B2 (ja) * 2017-02-23 2022-04-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 化合物ｉｉｉの新しい医学的使用
JP7166754B2 (ja) * 2017-11-22 2022-11-08 沢井製薬株式会社 ダサチニブ無水物含有製剤
EP3501506B1 (en) 2017-12-19 2019-10-09 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising brexpiprazole
EP3545950A1 (en) 2018-03-26 2019-10-02 Adamed sp. z o.o. Pharmaceutical composition comprising brexpiprazole
JPWO2021029020A1 (hr) * 2019-08-13 2021-02-18
WO2021095092A1 (ja) * 2019-11-11 2021-05-20 大塚製薬株式会社 口腔内崩壊錠
CN112168794A (zh) * 2020-10-27 2021-01-05 浙江诺得药业有限公司 一种布瑞哌唑片的制备方法
WO2022218358A1 (zh) * 2021-04-13 2022-10-20 上海博志研新药物技术有限公司 一种布瑞哌唑物口腔薄膜剂、其制备方法及应用
EP4374856A1 (en) 2022-11-23 2024-05-29 Sanovel Ilac Sanayi Ve Ticaret A.S. A process for tablets comprising brexpiprazole

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562375B1 (en) * 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
AU2002353659A1 (en) * 2001-12-18 2003-07-15 Synthon B.V. Simvastatin dosage forms
AU2003223093B2 (en) * 2002-05-03 2010-02-04 Israel Institute For Biological Research Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
OA13050A (en) 2003-04-29 2006-11-10 Pfizer Ltd 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension.
CN100480279C (zh) * 2003-06-09 2009-04-22 陶氏环球技术公司 稳定的有机硼烷聚合反应引发剂和可聚合的组合物
JP2006061067A (ja) * 2004-08-26 2006-03-09 Asahi Kasei Life & Living Corp 酸素インジケーター
GB0504203D0 (en) * 2005-03-01 2005-04-06 Novartis Ag Organic compounds
EP2783688A1 (en) 2005-03-17 2014-10-01 Synhton B.V. Pharmaceutical tablets of crystalline type ii aripiprazole
JP4315393B2 (ja) 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
DE602006004694D1 (de) 2006-01-05 2009-02-26 Teva Pharma Feuchtgranulierungsmethode zur Herstellung pharmazeutischer Aripiprazolzusammensetzungen
JP4806595B2 (ja) * 2006-07-05 2011-11-02 富士フイルム株式会社 固体撮像素子駆動装置及びデジタルカメラ
JP4540700B2 (ja) * 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
WO2008106059A1 (en) * 2007-02-26 2008-09-04 Merck & Co., Inc. Formulations for cathepsin k inhibitors
JP5432720B2 (ja) * 2007-03-13 2014-03-05 武田薬品工業株式会社 ２−［［６−［（３ｒ）−３−アミノ−１−ピペリジニル］−３，４−ジヒドロ−３−メチル−２，４−ジオキソ−１（２ｈ）−ピリミジニル］メチル］−４−フルオロベンゾニトリルを含む固形製剤
RU2470635C2 (ru) * 2007-05-11 2012-12-27 Сантен Фармасьютикал Ко., Лтд. Профилактическое или терапевтическое средство, применяемое при заболеваниях заднего отдела глаза
TW200924768A (en) 2007-10-12 2009-06-16 Astrazeneca Ab Composition
JP5463564B2 (ja) * 2009-05-22 2014-04-09 国立大学法人信州大学 耐熱性及び耐塩性セルラーゼ製剤
TR201000948A1 (tr) 2010-02-09 2011-08-22 Sanovel İlaç San.Ve Ti̇c.A.Ş. Aripiprazol formülasyonları.
TWI636784B (zh) * 2011-04-05 2018-10-01 大塚製藥股份有限公司 含7-〔4-(4-苯並〔b〕噻吩-4-基-哌-1-基)丁氧基〕-1H-喹啉-2-酮之醫藥組成物與套組，以及彼之用途
US9839684B2 (en) 2011-04-06 2017-12-12 Biovaxim Limited Pharmaceutical compositions comprising inactivated HIV viral particles and non-pathogenic lactobacilli for the induction of antigen-specific immunotolerance
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه

Also Published As

Publication number Publication date
US20140234417A1 (en) 2014-08-21
KR102072371B1 (ko) 2020-02-03
DK2767285T3 (da) 2020-01-27
CA2851588A1 (en) 2013-04-18
NZ622639A (en) 2015-11-27
MY173370A (en) 2020-01-21
EP2767285B2 (en) 2025-02-19
EA201490783A1 (ru) 2014-07-30
WO2013054872A1 (ja) 2013-04-18
LT2767285T (lt) 2020-02-10
IN2014DN02055A (hr) 2015-05-15
US20210023078A1 (en) 2021-01-28
US20220331311A1 (en) 2022-10-20
TW201318651A (zh) 2013-05-16
CN103889425B (zh) 2018-08-03
UA114411C2 (uk) 2017-06-12
US20240277703A1 (en) 2024-08-22
US10307419B2 (en) 2019-06-04
JP2017088610A (ja) 2017-05-25
MX2014004135A (es) 2014-07-24
EP2767285A4 (en) 2015-03-11
ZA201402333B (en) 2015-07-29
EP2767285B1 (en) 2019-11-27
US20180008600A1 (en) 2018-01-11
AP2014007564A0 (en) 2014-04-30
SG2014013783A (en) 2014-06-27
SI2767285T1 (sl) 2020-03-31
SG10201608412SA (en) 2016-12-29
CO6950480A2 (es) 2014-05-20
US20190240215A1 (en) 2019-08-08
AU2012321723C1 (en) 2017-11-02
US20170165258A1 (en) 2017-06-15
IL231513A0 (en) 2014-04-30
JP6084161B2 (ja) 2017-02-22
CL2014000909A1 (es) 2014-11-21
CA2851588C (en) 2019-07-02
CN107397730A (zh) 2017-11-28
EA032930B1 (ru) 2019-08-30
AU2012321723A1 (en) 2014-05-15
ES2762479T5 (en) 2025-05-30
SI2767285T2 (sl) 2025-06-30
IL231513B (en) 2020-01-30
AU2012321723B2 (en) 2017-07-20
BR112014008603A2 (pt) 2017-04-18
US20160158227A1 (en) 2016-06-09
HUE047493T2 (hu) 2020-04-28
DK2767285T4 (da) 2025-04-22
MX376092B (es) 2025-03-07
TWI634908B (zh) 2018-09-11
HRP20200037T1 (hr) 2020-03-20
JPWO2013054872A1 (ja) 2015-03-30
FI2767285T4 (fi) 2025-05-08
PL2767285T3 (pl) 2020-04-30
KR20140075754A (ko) 2014-06-19
EP2767285A1 (en) 2014-08-20
PL2767285T5 (pl) 2025-06-02
PH12014500607A1 (en) 2014-04-21
ES2762479T3 (es) 2020-05-25
CY1122460T1 (el) 2021-01-27
JO3753B1 (ar) 2021-01-31
PT2767285T (pt) 2020-01-21
AR088319A1 (es) 2014-05-28
CN103889425A (zh) 2014-06-25

Similar Documents

Publication Publication Date Title
HRP20200037T4 (hr) TABLETA KOJA SADRŽI 7-[4- (4-BENZO [b] TIOFEN-4-YL-PIPERAZIN-1-YL) BUTOKSI]-1H-KINOLIN-2-ON ILI NJEGOVU SOL
HRP20151383T1 (hr) Farmaceutski pripravci koji sadrže nilotinib ili njegovu sol
AR100977A1 (es) Formulación compuesta para la administración oral que comprende ezetimiba y rosuvastatina, y un proceso para su preparación
HRP20230613T1 (hr) Tableta koja sadrži derivat metoksiureje i čestice manitola
HRP20161262T1 (hr) Tablete ulipristal acetata
MX2008011579A (es) Forma galenica divisible que permite una liberacion modificada del principio activo.
RU2006122599A (ru) Способ изготовления твердого, орально применяемого фармацевтического состава
HRP20191587T1 (hr) Formulacije s trenutnim oslobađanjem za oralnu primjenu supstituiranih kinazolinona
JP2009537478A5 (hr)
JP2010132654A5 (hr)
RU2019138248A (ru) Фармацевтическая композиция для перорального введения, содержащая энзалутамид
JP2022538214A (ja) ブルトン型チロシンキナーゼ阻害剤を含む経口固体錠剤及びその調製方法
WO2011147026A3 (en) A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
BRPI0606187A2 (pt) comprimidos com capacidade de dispersão da substáncia do fármaco melhorada
IN2014DE03239A (hr)
HRP20161340T1 (hr) Formulacije darunavira
RU2014119866A (ru) Твердые дозированные формы (s)-этил 2-амино-3-(2-амино-6(r)-1-(4-хлор-2-(3-метил-1н-пиразол-1-ил)фенил)-2,2,2-трифторэтокси)пиримидин-4-ил)фенил)пропаноата
EP1469031A3 (en) Granulation of nonionic cellulose ether
EA033291B1 (ru) Единица дозирования, содержащая рамиприл и бисопролола гемифумарат, способ ее получения и способ лечения гипертензии
CN102961355B (zh) 一种硫酸氢氯吡格雷片及其制备方法
JP2016033133A5 (hr)
WO2008100240A3 (en) Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
RU2016106384A (ru) Противотуберкулезная стабильная фармацевтическая композиция в форме таблетки с покрытием, содержащей гранулированный изониазид и гранулированный рифапентин, и способ ее приготовления
CN103271908A (zh) 含有替米沙坦和苯磺酸氨氯地平的口服片剂及其制备方法
HRP20191764T1 (hr) Soli nalmefena kao lijekovi za smanjenje potrošnje alkohola ili za sprečavanje prekomjerne konzumacije alkohola